Diamyd Completes Recruitment in Gene Therapy Pain Trial
Shares in Diamyd Medical AB edged up more than 6 percent Tuesday on news that the company completed recruitment in a 32-patient, Phase II trial of its gene therapy treatment for chronic cancer pain, NP2 Enkephalin.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter